Search

Displaying results 1741 - 1750 of 10000 in total
  1. Drug

    Letermovir

    go.drugbank.com/drugs/DB12070
    ApprovedInvestigational

    Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients.

  2. Drug

    Fursultiamine

    go.drugbank.com/drugs/DB08966
    Approved

    Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.

    Mixtures: ALINAMIN EX PLUS
  3. Drug

    Neratinib

    go.drugbank.com/drugs/DB11828
    ApprovedInvestigational

    Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. … Neratinib is currently under investigation for use in many other forms of cancer.

  4. Drug

    Carphenazine

    go.drugbank.com/drugs/DB01038
    ApprovedWithdrawn

    Carphenazine is an antipsychotic drug, used in hospitalized patients in the management of chronic schizophrenic psychoses.

  5. Drug

    Tegafur

    go.drugbank.com/drugs/DB09256
    ApprovedInvestigational

    It is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with [DB09257] and [DB03209], or along with [DB00544] as [DB09327]. … When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the

    International brands: ESUEEW AN T
  6. Drug

    Fexofenadine

    go.drugbank.com/drugs/DB00950
    ApprovedInvestigational

    Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. … [L4269] It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier[L10779] - this is in contrast to previous first-generation

  7. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.

  8. Drug

    Arformoterol

    go.drugbank.com/drugs/DB01274
    Approved

    The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients … It works by relaxing muscles in the airways to improve breathing.

  9. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    [L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation … On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).

    Synonyms: N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDE N-((2R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODOANILINO)BENZAMIDE, (-)-N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDE
  10. Drug

    Dequalinium

    go.drugbank.com/drugs/DB04209
    Approved

    [A249255] First used as an antiseptic and disinfectant in the 1950s, dequalinium is still found in various OTC products to treat conditions of oral infections and inflammation. … [A249255] It is also used in vaginal tablets to treat bacterial vaginosis.[L42190]